Management of relapse after allo-SCT for AML and the role of second transplantation

被引：0
|
作者：
B N Savani
S Mielke
N Reddy
S Goodman
M Jagasia
K Rezvani
机构：
[1] Hematology and Stem Cell Transplantation Section,Division of Hematology/Oncology, Department of Medicine
[2] Vanderbilt University Medical Center,Division of Hematology and Oncology, Department of Internal Medicine II
[3] Allogeneic Stem Cell Transplant Center,Department of Haematology
[4] Julius Maximilian University,undefined
[5] Hammersmith Hospitals Trust,undefined
[6] Imperial College London,undefined
来源：
Bone Marrow Transplantation | 2009年 / 44卷
关键词：
AML; relapse; transplantation; DLI;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Relapse after allo-SCT for AML carries very poor prognosis. Second allo-SCT, although curative, is not an appropriate treatment option for a large number of relapsing patients (only 2–20% patients receive a second allo-SCT), and efforts to increase the number of patients who may benefit from a second allo-SCT are ongoing. In addition, understanding the varied biological processes that are operative in disease relapse has encouraged the development of novel therapies, and could be beneficial to patients who are currently managed conservatively with supportive care for relapsed disease. Incorporating novel combinations of drugs with immunomodulation, although theoretically attractive, should be tested in the setting of clinical trials. In this review, we discuss the currently available approaches for relapsed AML after allo-SCT.
引用
收藏
页码：769 / 777
页数：8
相关论文
共 50 条
  • [1] Management of relapse after allo-SCT for AML and the role of second transplantation
    Savani, B. N.
    Mielke, S.
    Reddy, N.
    Goodman, S.
    Jagasia, M.
    Rezvani, K.
    BONE MARROW TRANSPLANTATION, 2009, 44 (12) : 769 - 777
  • [2] Evaluation of BM cytomorphology after allo-SCT in patients with AML
    Christopeit, M.
    Miersch, K.
    Klyuchnikov, E.
    Haferlach, T.
    Binder, M.
    Zabelina, T.
    Ayuk, F.
    Schafhausen, P.
    Zander, A. R.
    Bokemeyer, C.
    Kroeger, N.
    Bacher, U.
    BONE MARROW TRANSPLANTATION, 2012, 47 (12) : 1538 - 1544
  • [3] Evaluation of BM cytomorphology after allo-SCT in patients with AML
    M Christopeit
    K Miersch
    E Klyuchnikov
    T Haferlach
    M Binder
    T Zabelina
    F Ayuk
    P Schafhausen
    A R Zander
    C Bokemeyer
    N Kröger
    U Bacher
    Bone Marrow Transplantation, 2012, 47 : 1538 - 1544
  • [4] Allo-SCT using BU, CY and melphalan for children with AML in second CR
    Beier, R.
    Albert, M. H.
    Bader, P.
    Borkhardt, A.
    Creutzig, U.
    Eyrich, M.
    Ehlert, K.
    Gruhn, B.
    Greil, J.
    Handgretinger, R.
    Holter, W.
    Klingebiel, T.
    Kremens, B.
    Lang, P.
    Mauz-Koerholz, C.
    Meisel, R.
    Mueller, I.
    Peters, C.
    Reinhardt, D.
    Sedlacek, P.
    Schulz, A.
    Schuster, F. R.
    Schrauder, A.
    Strahm, B.
    Sykora, K. W.
    Woessmann, W.
    Zimmermann, M.
    Sauer, M. G.
    BONE MARROW TRANSPLANTATION, 2013, 48 (05) : 651 - 656
  • [5] Allo-SCT using BU, CY and melphalan for children with AML in second CR
    R Beier
    M H Albert
    P Bader
    A Borkhardt
    U Creutzig
    M Eyrich
    K Ehlert
    B Gruhn
    J Greil
    R Handgretinger
    W Holter
    T Klingebiel
    B Kremens
    P Lang
    C Mauz-Körholz
    R Meisel
    I Müller
    C Peters
    D Reinhardt
    P Sedlacek
    A Schulz
    F R Schuster
    A Schrauder
    B Strahm
    K W Sykora
    W Wössmann
    M Zimmermann
    M G Sauer
    Bone Marrow Transplantation, 2013, 48 : 651 - 656
  • [6] Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT
    M Tobiasson
    R Olsson
    E Hellström-Lindberg
    J Mattsson
    Bone Marrow Transplantation, 2011, 46 : 719 - 726
  • [7] Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT
    Tobiasson, M.
    Olsson, R.
    Hellstrom-Lindberg, E.
    Mattsson, J.
    BONE MARROW TRANSPLANTATION, 2011, 46 (05) : 719 - 726
  • [8] Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT
    Rautenberg, Christina
    Nachtkamp, Kathrin
    Dienst, Ariane
    Schmidt, Pia Verena
    Heyn, Claudia
    Kondakci, Mustafa
    Germing, Ulrich
    Haas, Rainer
    Kobbe, Guido
    Schroeder, Thomas
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (04) : 348 - 354
  • [9] Prognostic factors in allo-SCT of elderly patients with AML
    J Krauter
    K Wagner
    M Stadler
    E Dammann
    M Zucknick
    M Eder
    S Buchholz
    E Mischak-Weissinger
    B Hertenstein
    A Ganser
    Bone Marrow Transplantation, 2011, 46 : 545 - 551
  • [10] Prognostic factors in allo-SCT of elderly patients with AML
    Krauter, J.
    Wagner, K.
    Stadler, M.
    Dammann, E.
    Zucknick, M.
    Eder, M.
    Buchholz, S.
    Mischak-Weissinger, E.
    Hertenstein, B.
    Ganser, A.
    BONE MARROW TRANSPLANTATION, 2011, 46 (04) : 545 - 551
12345